Compare Biogen Inc (BIIB) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Biogen Inc vs Quantumscape Corp — how do they compare? Biogen Inc trades at $202.7 (market cap $30.60B), while Quantumscape Corp trades at $6.37 (market cap $3.81B). The key difference: Biogen Inc is far larger — about 8× Quantumscape Corp's market cap, and Biogen Inc is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| BIIB | QS | |
|---|---|---|
Market Cap | $30.60B | $3.81B |
Sector | Health | Consumer Cyclical |
52-Week High | $216.63 | $18.44 |
52-Week Low | $128.93 | $4.89 |
Enterprise Value | $37.67B | $3.02B |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
